Attovia Therapeutics (ATTO) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($744.6 million vs $657.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | NVCT |
|---|---|---|
| Share price | $16.31 | $20.13 |
| Market cap | $744.57M | $657.12M |
| 1-day change | -0.67% | -0.79% |
| YTD return | — | +166.62% |
| 1-year return | — | +223.11% |
| EPS (TTM) | $-2.74 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $29.28 |
| 52-week low | $15.48 | $5.55 |
| Distance from 52-week high | -41.75% | -31.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +158.74% | +75.86% |
| Average volume | 457.37K | 215.43K |
| Shares outstanding | 45.65M | 32.64M |
| Employees | 44 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ATTO vs NVCT FAQ
Which is bigger, Attovia Therapeutics or Nuvectis Pharma?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $744.57M compared with $657.12M for Nuvectis Pharma (NVCT).
Are Attovia Therapeutics and Nuvectis Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics and Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma.